查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916500

全球临床试验市场：市场规模、占有率、成长率、产业分析、按类型、应用和地区划分的考虑因素以及未来预测（2026-2034）

Clinical Trials Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 151 Pages | 商品交期: 请询问到货日

价格

临床试验市场的成长驱动因素

全球临床试验市场在新药、生物製品和医疗器材的研发中发挥着至关重要的作用，用于评估其安全性、有效性和治疗价值。 2025年，全球临床试验市场规模达到649.4亿美元，反映了製药、生技和医疗器材公司的强劲需求。预计到2026年，该市场规模将成长至692.7亿美元，并在2034年进一步扩大至1,207.5亿美元，显示临床研究在现代医疗创新中的重要性日益凸显。

临床试验涵盖多个阶段和治疗领域，旨在支持新疗法的监管审批和商业化。研发投入的增加、慢性病盛行率的上升以及对合约研究组织 (CRO) 的日益依赖是市场扩张的关键驱动因素。 IQVIA Inc.、美国实验室控股公司 (Laboratory Corporation of America Holdings) 和辉瑞公司 (Pfizer Inc.) 等领先企业正积极利用先进技术来提高试验效率和数据品质。

市场动态

市场驱动因素

包括癌症、糖尿病、心血管疾病和神经系统疾病在内的慢性病在全球日益加重，是临床试验市场的主要驱动因素。创新有效疗法的需求不断增长，导致全球临床研究数量显着增加。此外，不断扩大的药物研发管线也推动了临床试验数量的增加，持续促进市场成长。

市场限制因子

儘管需求强劲，但熟练专业人员数量有限以及临床试验成本高昂等因素限制着市场的发展。进行临床试验需要经验丰富的研究人员、临床医生和法规专家，而合格人员的短缺会导致进度延误。此外，法规遵循、复杂的试验方案和较低的成功率都会增加整体研发成本，进而限制市场扩张。

市场机会

将临床研究外包给合约研究组织 (CRO) 的做法日益增多，这为企业带来了巨大的成长机会。製药和生物技术公司与 CRO 合作，以降低营运成本、利用专业知识并缩短试验时间。这一趋势对没有内部研究基础设施的中小型企业尤其有利。

市场挑战

病患招募和保留仍然是重大挑战，这通常会导致研究週期延长和成本超支。区域监管差异以及关于资料隐私和知情同意的严格伦理要求也使临床试验的实施变得复杂。

市场趋势

临床试验市场最显着的趋势之一是製药和生技公司不断增加研发投入。人工智慧 (AI) 与先进数据分析的融合正在变革临床试验设计、病患招募和数据解读。此外，分散式临床试验 (DCT) 也日益普及，透过数位健康技术实现远距参与，进而改善病患就医途径。

由于病患群体多样化、成本优势以及有利的监管改革，中国和印度等新兴市场也正成为极具吸引力的临床研究目的地。

依细分市场分析

按阶段划分，III 期临床试验因其规模庞大、投资需求高，占据市场主导地位，导致越来越多的临床试验外包给合约研究组织 (CRO)。按应用领域划分，肿瘤学领域占据最大占有率，这主要归功于癌症发病率的上升以及对标靶治疗的需求。中枢神经系统疾病和代谢性疾病也因发病率的上升而呈现强劲成长动能。

区域展望

北美地区凭藉高额研发投入、强大的合约研究组织 (CRO) 实力以及先进的研究基础设施，预计将在 2025 年以 43.90% 的市场占有率引领临床试验市场。美国仍然是最大的贡献地区。欧洲在製药公司研发投入的推动下持续稳定成长，而亚太地区则因中国、印度和日本临床活动的增加而实现最快成长。拉丁美洲以及中东和非洲正成为进行临床试验的成本效益较高的地区。

"全球临床试验市场" 报告对市场规模、成长驱动因素、限制因素、机会、趋势、细分、区域展望、竞争格局和关键发展进行了全面评估。报告深入分析了 2025 年、2026 年和 2034 年的市场表现，并从定性和定量两个方面深入探讨了创新、外包和全球研发投资如何塑造临床试验行业的未来。

主要成长驱动因素包括研发支出增加、外包给合约研究组织 (CRO) 的规模扩大、人工智慧和分散式试验模式等先进技术的应用，以及新兴地区临床活动的拓展。儘管仍存在一些挑战，例如试验成本上升、熟练人员短缺、监管复杂以及患者招募问题，但 IQVIA Inc.、ICON plc 和 Syneos Health 等主要参与者的持续创新和流程优化正在帮助缓解这些障碍。

总之，从 2025 年、2026 年和 2034 年的视角来看，临床试验市场仍然是全球医疗保健创新的基石，推动着科学进步、监管审批以及各个治疗领域下一代疗法的开发。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家/地区临床试验数量（2025 年）
  • 主要公司研发支出
  • 主要国家新增临床试验计划
  • 关键趋势：併购、合作等
  • 新冠疫情对市场的影响

第五章：全球临床试验市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依阶段划分
    • I期
    • II期
    • III期
    • IV期
  • 市场分析、洞察与预测：依应用划分
    • 肿瘤学
    • 中枢神经系统疾病
    • 心臟病学
    • 传染病
    • 代谢性疾病
    • 肾臟科和肾臟医学
    • 其他
  • 市场分析、洞察与预测：按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 世界其他地区 (ROW)

第六章 北美临床试验市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲临床试验市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区临床试验市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚亚洲
    • 亚太其他地区

第九章：世界其他地区（ROW）临床试验市场分析：洞察与预测（2021-2034）

第十章：竞争分析

  • 全球市占率分析（2025）
  • 公司简介
  • IQVIA Inc.
  • 美国实验室控股公司
  • 赛默飞世尔科技公司
  • Parexel International Corporation
  • Medpace Holdings, Inc.
  • Icon plc
  • Syneos Health
  • 药明康德
  • 查尔斯河实验室
  • 辉瑞公司
  • 礼来公司
Product Code: FBI106930

Growth Factors of clinical trials Market

The global clinical trials market plays a foundational role in the development of new pharmaceuticals, biologics, and medical devices by evaluating their safety, efficacy, and therapeutic value. In 2025, the global clinical trials market size was valued at USD 64.94 billion, reflecting strong demand from pharmaceutical, biotechnology, and medical device companies. The market is projected to grow to USD 69.27 billion in 2026 and further expand to USD 120.75 billion by 2034, highlighting the increasing importance of clinical research in modern healthcare innovation.

Clinical trials are conducted across multiple phases and therapeutic areas to support regulatory approvals and commercialization of novel treatments. Rising investments in research and development, increasing prevalence of chronic diseases, and growing reliance on Contract Research Organizations (CROs) are key factors contributing to market expansion. Major companies such as IQVIA Inc., Laboratory Corporation of America Holdings, and Pfizer Inc. are actively leveraging advanced technologies to improve trial efficiency and data quality.

Market Dynamics

Market Drivers

The rising global burden of chronic diseases, including cancer, diabetes, cardiovascular disorders, and neurological conditions, is a major driver for the clinical trials market. The need for innovative and effective therapeutics has significantly increased the number of clinical studies conducted worldwide. Additionally, the growing volume of clinical trials-supported by expanding pharmaceutical pipelines-continues to fuel market growth.

Market Restraints

Despite strong demand, the market faces constraints related to the limited availability of skilled professionals and the high cost of conducting clinical studies. Clinical trial execution requires experienced researchers, clinicians, and regulatory experts, and shortages in qualified personnel can delay timelines. Furthermore, regulatory compliance, complex study protocols, and low success rates increase overall development costs, restraining market expansion.

Market Opportunities

Increasing outsourcing of clinical research to CROs presents a major growth opportunity. Pharmaceutical and biotechnology companies are partnering with CROs to reduce operational costs, access specialized expertise, and accelerate trial timelines. This trend is particularly beneficial for small and mid-sized companies lacking in-house research infrastructure.

Market Challenges

Patient recruitment and retention remain significant challenges, often leading to extended study durations and cost overruns. Regulatory variability across regions and strict ethical requirements related to data privacy and informed consent also add complexity to clinical trial execution.

Market Trends

One of the most prominent trends in the clinical trials market is the increasing investment in R&D by pharmaceutical and biotechnological companies. The integration of artificial intelligence (AI) and advanced data analytics is transforming trial design, patient recruitment, and data interpretation. Additionally, decentralized clinical trials (DCTs) are gaining traction, enabling remote participation through digital health technologies and improving patient accessibility.

Emerging markets such as China and India are also becoming attractive destinations for clinical research due to diverse patient populations, cost advantages, and supportive regulatory reforms.

Segmentation Analysis

By phase, Phase III clinical trials dominate the market due to their large scale, high investment requirements, and increasing outsourcing to CROs. By application, oncology holds the largest share, driven by the growing prevalence of cancer and the need for targeted therapies. CNS disorders and metabolic diseases are also witnessing strong growth due to rising disease incidence.

Regional Outlook

North America dominated the clinical trials market with a 43.90% share in 2025, supported by high R&D expenditure, strong CRO presence, and advanced research infrastructure. The U.S. remains the largest contributor within the region. Europe follows with steady growth driven by pharmaceutical R&D investments, while Asia Pacific is the fastest-growing region due to increasing clinical activity in China, India, and Japan. Latin America and the Middle East & Africa are emerging as cost-effective regions for conducting clinical studies.

Competitive Landscape

The market is moderately consolidated, with leading CROs and service providers focusing on service expansion, digital transformation, and strategic partnerships. Key players include IQVIA Inc., ICON plc, and Syneos Health. These companies emphasize technology-driven platforms, decentralized trials, and global site networks to strengthen their market position.

Report Coverage

The clinical trials market report delivers a comprehensive assessment of market size, growth drivers, restraints, opportunities, trends, segmentation, regional outlook, competitive landscape, and key industry developments. The analysis strictly evaluates market performance for 2025, 2026, and 2034, providing both qualitative and quantitative insights into how innovation, outsourcing, and global R&D investments are shaping the future of the clinical trials industry.

Conclusion

The global clinical trials market is positioned for steady and sustained growth, driven by the increasing need for innovative therapies, expanding pharmaceutical and biotechnology pipelines, and rising global disease burden. With the market valued at USD 64.94 billion in 2025, its progression to USD 69.27 billion in 2026 reflects continued investment in research activities and greater reliance on structured clinical development pathways. The long-term expansion to USD 120.75 billion by 2034 underscores the critical role clinical trials play in bringing safe and effective drugs, biologics, and medical devices to market.

Key growth enablers include higher R&D spending, greater outsourcing to Contract Research Organizations, adoption of advanced technologies such as artificial intelligence and decentralized trial models, and expanding clinical activity in emerging regions. While challenges such as high trial costs, skilled workforce shortages, regulatory complexity, and patient recruitment issues persist, ongoing innovation and process optimization by leading players such as IQVIA Inc., ICON plc, and Syneos Health are helping to mitigate these barriers.

Overall, evaluated strictly for 2025, 2026, and 2034, the clinical trials market remains a cornerstone of global healthcare innovation, enabling scientific advancement, regulatory approvals, and the development of next-generation treatments across diverse therapeutic areas.

Segmentation By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Application

  • Oncology
  • CNS Disorder
  • Cardiology
  • Infectious Disease
  • Metabolic Disorder
  • Renal/Nephrology
  • Others

By Region

  • North America (By Phase, By Application, and By Country)
    • U.S.
    • Canada
  • Europe (By Phase, By Application, and By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific ( By Phase, By Application, and By Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Phase, By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Number of Clinical Trials - by Key Countries, 2025
  • 4.2. R&D expenditures, by Key Players
  • 4.3. New Clinical Trials Initiatives, by Key Countries
  • 4.4. Key Industry Developments (Mergers, Partnerships, Acquisitions, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Phase
    • 5.1.1. Phase I
    • 5.1.2. Phase II
    • 5.1.3. Phase III
    • 5.1.4. Phase IV
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Oncology
    • 5.2.2. CNS Disorder
    • 5.2.3. Cardiology
    • 5.2.4. Infectious Disease
    • 5.2.5. Metabolic Disorder
    • 5.2.6. Renal/Nephrology
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Rest of the World

6. North America Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Phase
    • 6.1.1. Phase I
    • 6.1.2. Phase II
    • 6.1.3. Phase III
    • 6.1.4. Phase IV
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Oncology
    • 6.2.2. CNS Disorder
    • 6.2.3. Cardiology
    • 6.2.4. Infectious Disease
    • 6.2.5. Metabolic Disorder
    • 6.2.6. Renal/Nephrology
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Phase
    • 7.1.1. Phase I
    • 7.1.2. Phase II
    • 7.1.3. Phase III
    • 7.1.4. Phase IV
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Oncology
    • 7.2.2. CNS Disorder
    • 7.2.3. Cardiology
    • 7.2.4. Infectious Disease
    • 7.2.5. Metabolic Disorder
    • 7.2.6. Renal/Nephrology
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Phase
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
    • 8.1.4. Phase IV
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Oncology
    • 8.2.2. CNS Disorder
    • 8.2.3. Cardiology
    • 8.2.4. Infectious Disease
    • 8.2.5. Metabolic Disorder
    • 8.2.6. Renal/Nephrology
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Rest of the World Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Phase
    • 9.1.1. Phase I
    • 9.1.2. Phase II
    • 9.1.3. Phase III
    • 9.1.4. Phase IV
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Oncology
    • 9.2.2. CNS Disorder
    • 9.2.3. Cardiology
    • 9.2.4. Infectious Disease
    • 9.2.5. Metabolic Disorder
    • 9.2.6. Renal/Nephrology
    • 9.2.7. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. IQVIA Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Laboratory Corporation of America Holdings
      • 10.2.2.1. Overview
      • 10.2.2.2. Services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Thermo Fisher Scientific Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Parexel International Corporation
      • 10.2.4.1. Overview
      • 10.2.4.2. Services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Medpace Holdings, Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Icon plc
      • 10.2.6.1. Overview
      • 10.2.6.2. Services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Syneos Health
      • 10.2.7.1. Overview
      • 10.2.7.2. Services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. WuXi AppTec
      • 10.2.8.1. Overview
      • 10.2.8.2. Services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Charles River Laboratories
      • 10.2.9.1. Overview
      • 10.2.9.2. Services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. Pfizer Inc.
      • 10.2.10.1. Overview
      • 10.2.10.2. Services
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)
    • 10.2.11. Lilly
      • 10.2.11.1. Overview
      • 10.2.11.2. Services
      • 10.2.11.3. SWOT Analysis
      • 10.2.11.4. Recent Developments
      • 10.2.11.5. Strategies
      • 10.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Clinical Trials Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 2: Global Clinical Trials Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Clinical Trials Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 4: North America Clinical Trials Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 5: North America Clinical Trials Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 6: North America Clinical Trials Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 7: Europe Clinical Trials Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 8: Europe Clinical Trials Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 9: Europe Clinical Trials Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Clinical Trials Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 11: Asia Pacific Clinical Trials Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 12: Asia Pacific Clinical Trials Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Rest of the World Clinical Trials Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 14: Rest of the World Clinical Trials Market Revenue (USD billion) Forecast, by Application, 2021-2034

List of Figures

  • Figure 1: Global Clinical Trials Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Clinical Trials Market Value Share (%), by Phase, 2025 & 2034
  • Figure 3: Global Clinical Trials Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Clinical Trials Market Value (USD billion), by Region, 2025 & 2034
  • Figure 5: North America Clinical Trials Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 6: North America Clinical Trials Market Value Share (%), by Phase, 2025
  • Figure 7: North America Clinical Trials Market Value (USD billion), by Application, 2025 & 2034
  • Figure 8: North America Clinical Trials Market Value Share (%), by Application, 2025
  • Figure 9: North America Clinical Trials Market Value (USD billion), By Country, 2025 & 2034
  • Figure 10: North America Clinical Trials Market Value Share (%), By Country, 2025
  • Figure 11: Europe Clinical Trials Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 12: Europe Clinical Trials Market Value Share (%), by Phase, 2025
  • Figure 13: Europe Clinical Trials Market Value (USD billion), by Application, 2025 & 2034
  • Figure 14: Europe Clinical Trials Market Value Share (%), by Application, 2025
  • Figure 15: Europe Clinical Trials Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Clinical Trials Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Clinical Trials Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 18: Asia Pacific Clinical Trials Market Value Share (%), by Phase, 2025
  • Figure 19: Asia Pacific Clinical Trials Market Value (USD billion), by Application, 2025 & 2034
  • Figure 20: Asia Pacific Clinical Trials Market Value Share (%), by Application, 2025
  • Figure 21: Asia Pacific Clinical Trials Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Clinical Trials Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Rest of the World Clinical Trials Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 24: Rest of the World Clinical Trials Market Value Share (%), by Phase, 2025
  • Figure 25: Rest of the World Clinical Trials Market Value (USD billion), by Application, 2025 & 2034
  • Figure 26: Rest of the World Clinical Trials Market Value Share (%), by Application, 2025
  • Figure 27: Global Clinical Trials Market Share (%), By Company, 2025